Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease

Abstract

With more effective prophylactic treatment and an increased time of survival, noninfectious conditions associated with human immunodeficiency virus (HIV) disease are being recognized with increasing frequency in HIV patients. Cardiac involvement in HIV-infected patients varies from clinically silent to a fatal disease with a direct cardiac cause of mortality estimated at 1% to 6%. Pericardial effusion, pericarditis, myocarditis, cardiomyopathy, endocarditis, and pulmonary hypertension are known cardiac manifestations associated with HIV infection. Coronary artery disease (CAD) has not been a recognized complication of HIV disease, although some recent case reports have suggested occurrence of premature CAD and accel erated atherogenesis in HIV-infected patients. The role of protease inhibitors have been suggested in the development of this complication. After reviewing records of the last 7 years, the authors found 10 cases of acute coronary syndrome in HIV-infected patients who had no other risk factor for CAD except smoking. The presence of CAD was confirmed by angiog raphy or autopsy. The mean CD4 count was 380 cells/mm³, and the mean duration between the diagnosis of HIV infection and CAD was 7.5 years. Four patients had single-vessel disease, 1 patient had 2-vessel disease, and 5 patients had 3-vessel disease. Three patients underwent coronary bypass surgery and 1 patient died of cardiogenic shock. CAD may be associated with HIV disease.

Get full access to this article

View all access options for this article.

References

Autran BR , Gorin I. , Leibowitch M., et al : AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease. Lancet 1:767-768, 1983.

Calabrese LH , Proffitt MR , Yen-Leberman B., et al : Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome(AIDS) associated with isolation of retrovirus from myocardium Ann Intern Med 107:691-692, 1987.

Mehta NJ , Khan IA , Mehta RN, et al : HIV-related pulmonary hypertension: Analytic review of 131 cases Chest 118:1133-1141, 2000.

Paton P. , Tabib A. , Loire R., et al : Coronary artery lesions and human immunodeficiency infection Res Vorol 144:225-231, 1993.

Henry K. , Melrose H. , Huebsch J., et al : Severe premature coronary artery disease with protease inhibitors Lancet 351:1328, 1998.

Behrens G. , Schmidt H. , Meyer D., et al : Vascular complications associated with the use of HIV protease inhibitors Lancet 351:1958, 1998.

Gallet B. , Pulik M. , Genet P., et al : Vascular complications associated with use of HIV protease inhibitors Lancet 351:1959, 1998.

Fabricant CG , Fabrican J. , Litrenta MM, et al : Virus-induced atherosclerosis J Exp Med 148:335-340, 1978.

Shah PK : Plaque disruption and thrombosis: Potential role of inflammation and infection Cardiol Clin 17:271-281, 1999.

10.

Libby P. , Egan D. , Skarlatos S. : Roles of infectious agents in atherogenesis and restenosis: An assessment of the evidence and need for future research Circulation 96:4095-4103, 1997.

11.

Karmochkine M. , Ankri A. , Calvez V., et al : Plasma hypercoagulability is correlated to plasm HIV load Thromb Haemost 80:208-209, 1998.

12.

Hammer SM , Squires KE , Hughes MD, et al : A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 337:725-733, 1997.

13.

Palella Fjj , Delaney KM , Moorman AC, et al : Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection : HIV Outpatient Study Investigators N Engl J Med 338:853-860, 1998.

14.

Walli R. , Herfort O. , Michl GM, et al : Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients AIDS 12:F167-173, 1998.

15.

Carr A. , Samaras K. , Burton S., et al : A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12:F51-58, 1998.

16.

Beherens G. , Dejam A. , Schmidt H., et al : Impaired glucose tolerance and beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors AIDS 13:F63-70, 1999 .

17.

Sullivan AK , Nelson MR : Marked hyperlipidemia on ritonavir therapy AIDS 11:938-939, 1997.

18.

Sereger S. , Bogner JR , Walli R., et al : Hyperlipidemia under treatment of protease inhibitors Infection 27:77-81, 1999.

19.

Periard D. , Telenti A. , Sundre P., et al : Atherogenic dyslipidemias in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study Circulation 100:700-705, 1999.

20.

Henry K. , Melrose J. , Huebesch J., et al : Atorvastatin and gemfibrozil for protease inhibitor related lipid abnormalities Lancet 352:1031-1032, 1998 .

21.

Hewitt RG , Shelton MJ , Esch LD : Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 positive patients AIDS 13:867-869, 1999.

22.

Nauss-Karol C. , Drake J. , Buss N., et al : Changes in serum lipids in HIV-infected patients treated with HAART regimens containing one or two protease inhibitors AIDS 12:S52, 1998.